Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Active, not recruiting · NCT04009109 · Registry updated 2025-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell myeloma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-12-18 | NCT04009109 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alliance Foundation Trials, LLC. | 12 |
| Celgene Corporation | 20 |
| Janssen Scientific Affairs, LLC | 37 |
| Takeda | 163 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Gibbs Cancer Center & Research Institute/Spartanburg Regional Healthcare | Spartanburg | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Northern Light Eastern Maine Medical Center | Bangor | United States | 9 |
| SUNY Upstate Medical Center | Syracuse | United States | 7 |
| University of Nebraska Medical Center | Omaha | United States | 1 |
| University of North Carolina | Chapel Hill | United States | 38 |